TSBX
- Turnstone Biologics Corp.
()
Overview
Company Summary
Turnstone Biologics Corp. (TSBX) is a biotechnology company focused on the development of innovative oncolytic viral immunotherapies. Oncolytic viral immunotherapy is a type of treatment that harnesses the power of viruses to stimulate the immune system and fight against cancer.
TSBX specializes in the design and development of genetically engineered viruses that selectively target and infect cancer cells while leaving healthy cells unharmed. These viruses are designed to replicate inside the cancer cells, triggering the release of viral particles and antigens that help to stimulate an anti-tumor immune response.
The company's lead product candidate, RIVAL-01, is a proprietary oncolytic viral immunotherapy that is currently being evaluated in clinical trials for multiple solid tumor types. RIVAL-01 is designed to not only directly kill cancer cells but also to stimulate the immune system to recognize and attack cancer cells throughout the body.
In addition to RIVAL-01, Turnstone Biologics focuses on research and development activities to advance its pipeline of novel oncolytic viral immunotherapies. The company utilizes its deep understanding of cancer biology, virology, and immunology to develop powerful and targeted treatments for various types of cancer.
By leveraging the body's immune system and the potential of viruses, Turnstone Biologics is working towards providing more effective and safer treatment options for patients with hard-to-treat cancers. Their ultimate goal is to revolutionize cancer treatment by developing therapies that can improve patient outcomes and make a meaningful impact in the fight against cancer.